Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Atherosclerosis

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0021-9150(97)00181-0PMID 9544745
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of the genetic defect with LDL-receptor activity in cultured cells from patients with a clinical diagnosis of heterozygous familial hypercholesterolemia. The Familial Hypercholesterolaemia Regression Study Group.

  1997cited by this paper
• Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.

  1996cited by this paper
• Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect.

  1996cited by this paper
• Influence of apolipoprotein E genotypes on plasma lipid and lipoprotein concentrations: Results from a segregation analysis in pedigrees with molecularly defined familial hypercholesterolemia

  1996cited by this paper
• Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low‐density‐lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment

  1995cited by this paper
• Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway.

  1995cited by this paper
• Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation.

  1995cited by this paper
• Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.

  1995cited by this paper
• Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low‐density lipoprotein receptor gene?

  1995cited by this paper
• Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene.

  1994cited by this paper
• Evidence of non-deficient low-density lipoprotein receptor patients in a pool of subjects with clinical familial hypercholesterolemia profile.

  1994cited by this paper
• Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations.

  1993cited by this paper
• Deletion of exon 15 of the LDL receptor gene is associated with a mild form of familial hypercholesterolemia. FH-Espoo.

  1993cited by this paper
• Genetic Determinants of Responsiveness to the HMG‐CoA Reductase Inhibitor Fluvastatin in Patients With Molecularly Defined Heterozygous Familial Hypercholesterolemia

  1993cited by this paper
• Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia.

  1993cited by this paper
• Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia.

  1993cited by this paper
• Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia.

  1993cited by this paper
• Molecular genetics of the LDL receptor gene in familial hypercholesterolemia

  1992cited by this paper
• Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.

  1991cited by this paper
• The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.

  1990cited by this paper
• Genotypic and phenotypic variation in familial hypercholesterolemia.

  1989cited by this paper
• The LDL receptor gene: a mosaic of exons shared with different proteins.

  1985cited by this paper

• Lipids dysregulation in diseases: core concepts, targets and treatment strategies

  2025cites this paper
• Functional analysis of LDLR variants reveals that the novel p.(Ser610Tyr) variant in the YMDD motif drastically impacts LDL uptake

  2025cites this paper
• Establishing the Mutational Spectrum of Hungarian Patients with Familial Hypercholesterolemia

  2022cites this paper
• An Educational Assessment of Evidence Used for Variant Classification: A Report of the Association for Molecular Pathology.

  2022cites this paper
• The Power to Predict: Does LDLR mutation status determine statin responsiveness?

  2022cites this paper
• Multiparametric platform for profiling lipid trafficking in human leukocytes

  2022cites this paper
• Influence of the LDL-receptor genotype on statin response in heterozygous familial hypercholesterolemia: insights from the Canadian FH Registry.

  2021cites this paper
• Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia

  2021cites this paper
• Structure–Function Relationships of LDL Receptor Missense Mutations Using Homology Modeling

  2019cites this paper
• Statins for children with familial hypercholesterolemia.

  2019cites this paper
• Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels.

  2019cites this paper
• Molecular mechanisms and genetic regulation in atherosclerosis

  2018cites this paper
• Statins for children with familial hypercholesterolemia.

  2017cites this paper
• Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction

  2015cites this paper
• Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment.

  2015cites this paper
• Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia.

  2014cites this paper
• Statins for children with familial hypercholesterolemia.

  2014cites this paper
• Accelerated Atherosclerosis in a Young Female with Familial Hypercholesterolemia

  2014cites this paper
• Treatment of homozygous familial hypercholesterolemia

  2014influential citation
• Resolving the Genetic Etiology of Hypercholesterolemia in Familial Combined Hyperlipidemia

  2013cites this paper
• Autosomal Dominant Hypercholesterolemia: Needs for Early Diagnosis and Cascade Screening in the Tunisian Population

  2013cites this paper
• Genetics of Dyslipidemia

  2012cites this paper
• In vitro functional characterization of missense mutations in the LDLR gene.

  2012cites this paper
• Discrimination Capacity of RAPD, ISSR and SSR Markers and of their Effectiveness in Establishing Genetic Relationship and Diversity among Egyptian and Saudi Wheat Cultivars

  2012cites this paper
• Pharmacogenomics of Cardiovascular Drugs

  2012cites this paper
• The logarithm of the triglyceride/HDL-cholesterol ratio is related to the history of cardiovascular disease in patients with familial hypercholesterolemia.

  2012cites this paper
• Familial hypercholesterolemia and triglyceride metabolism.

  2011cites this paper
• Pharmacometrics in dose finding or dose optimization of anti-retroviral and anti-tubercular drugs.

  2011cites this paper
• Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: data from the MedPed CZ database and the Czech population.

  2011cites this paper
• Moderate phenotypic expression of familial hypercholesterolemia in Tunisia.

  2010cites this paper
• Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease

  2009cites this paper
• LDLR promoter variant and exon 14 mutation on the same chromosome are associated with an unusually severe FH phenotype and treatment resistance

  2009cites this paper
• FAMILIAL HYPERCHOLESTEROLAEMIA IN NORTHWESTERN GREECE

  2008cites this paper
• Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolaemia.

  2007cites this paper
• Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients.

  2007cites this paper
• Nutrition-Related Genetic Diseases

  2007cites this paper
• Diagnosis of families with familial hypercholesterolaemia and/or Apo B-100 defect by means of DNA analysis of LDL-receptor gene mutations

  2007cites this paper
• Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing

  2006cites this paper
• Complex genetics of monogenic familial hypercholesterolemia

  2006cites this paper
• Low-Density Lipoprotein Receptor Genotype and Response to Pravastatin in Children With Familial Hypercholesterolemia: Substudy of an Intima-Media Thickness Trial

  2005cites this paper
• Severe Hypercholesterolemia in Four British Families With the D374Y Mutation in the PCSK9 Gene: Long-Term Follow-Up and Treatment Response

  2005cites this paper
• Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia.

  2005cites this paper
• Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia.

  2005cites this paper
• Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background

  2005cites this paper
• Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia

  2005cites this paper
• Mutations in low-density lipoprotein receptor gene as a cause of hypercholesterolemia in Taiwan.

  2005cites this paper
• HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice.

  2005cites this paper
• Update of the molecular basis of familial hypercholesterolemia in The Netherlands

  2005cites this paper
• Familial hypercholesterolemia in northwestern Greece

  2005cites this paper
• LDL‐receptor mutations in Europe

  2004cites this paper
• Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management.

  2004cites this paper
• Hypolipidemic treatment of heterozygous familial hypercholesterolemia: a lifelong challenge

  2004cites this paper
• Screening for point mutations in the LDL receptor gene in Bulgarian patients with severe hypercholesterolemia

  2004cites this paper
• FH clinical phenotype in Greek patients with LDL‐R defective vs. negative mutations

  2004cites this paper
• Pharmacogenetics of lipid diseases

  2004cites this paper
• Genetically defined hyperlipidemia.

  2004cites this paper
• Genetic diagnosis of familial hypercholesterolaemia: a mutation and a rare non-pathogenic amino acid variant in the same family.

  2004cites this paper
• For personal use. Only reproduce with permission from The Lancet.

  2004cites this paper
• Dyslipidaemia.

  2003cites this paper
• Risk of Fatal Stroke in Patients With Treated Familial Hypercholesterolemia: A Prospective Registry Study

  2003cites this paper
• Influence of LDL receptor gene mutations and the R3500Q mutation of the apoB gene on lipoprotein phenotype of familial hypercholesterolemic patients from a South European population

  2003cites this paper
• Asociación de factores lipídicos, genotipo de APOE y tipos de mutación del gen del receptor de LDL con el infarto agudo de miocardio en sujetos con hipercolesterolemia familiar heterocigota

  2002cites this paper
• LDL receptor mutation genotype and vascular disease phenotype in heterozygous familial hypercholesterolaemia

  2002cites this paper
• The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.

  2002cites this paper
• Risk of Fatal Stroke in Patients With Treated Familial Hypercholesterolemia

  2002cites this paper
• [Influence of plasma lipids, APOE genotype and type of LDL receptor gene mutations on myocardial infarction in subjects with familial hypercholesterolemia].

  2002cites this paper
• Effect of Simvastatin on markers of triglyceride‐rich lipoproteins in familial hypercholesterolaemia

  2002cites this paper
• Genetic characterization of Swedish patients with familial hypercholesterolemia: a heterogeneous pattern of mutations in the LDL receptor gene.

  2002cites this paper
• [Influence of FH Valencia 1 and 2 mutations of the LDL receptor gene on the response to simvastatin in subjects with molecularly defined heterozygous familial hypercholesterolemia in Spain].

  2001cites this paper
• Elevated apolipoprotein B‐48 and remnant‐like particle–cholesterol in heterozygous familial hypercholesterolaemia

  2001cites this paper
• Influencia de las mutaciones HF Valencia 1 y 2 del gen del receptor de LDL sobre la respuesta terapéutica a simvastatina en sujetos con hipercolesterolemia familiar heterocigota caracterizada molecularmente

  2001cites this paper
• Fh-Souassi: a founder frameshift mutation in exon 10 of the LDL-receptor gene, associated with a mild phenotype in Tunisian families.

  2001cites this paper
• LDL‐receptor gene mutations and the hypocholesterolemic response to statin therapy

  2001cites this paper
• Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.

  2001cites this paper
• Management of hypercholesterolemia.

  2001cites this paper
• A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom

  2001cites this paper
• How should FCHL be defined and how should we think about its metabolic bases?

  2001cites this paper
• Determinants of Variable Response to Statin Treatment in Patients With Refractory Familial Hypercholesterolemia

  2001cites this paper
• Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation.

  2000cites this paper
• Reduction of the genetic interval for lyphoedema-distichiasis to below 2 Mb.

  2000cites this paper
• FH-Freiburg: a novel missense mutation (C317Y) in growth factor repeat A of the low density lipoprotein receptor gene in a German patient with homozygous familial hypercholesterolemia.

  2000cites this paper
• Flow Cytometric Assessment of Effects of Fluvastatin on Low‐Density Lipoprotein Receptor Activity in Stimulated T‐Lymphocytes from Patients with Heterozygous Familial Hypercholesterolemia

  2000cites this paper
• Interstitial deletion of chromosome 17 (del(17)(q22q23.3)) confirms a link with oesophageal atresia

  2000cites this paper
• Interstitial deletion of chromosome 17 (del(17)(q22q23.3)) confirms a link with oesophageal atresia.

  2000cites this paper
• Mutations in the low-density-lipoprotein receptor gene in German patients with familial hypercholesterolaemia

  2000cites this paper
• Anatomie und Pathologie der Koronararterien

  2000cites this paper
• I705 variant in the low denisty lipoprotein receptor gene has no effect on plasma cholesterol levels.

  2000cites this paper
• Mosaicism in Alport syndrome with genetic counselling.

  2000cites this paper
• Lipid‐lowering response of the HMG‐CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low‐density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia

  2000cites this paper
• Normolipidemia and hypercholesterolemia in persons heterozygous for the same 1592+5G→A splice site mutation in the low‐density lipoprotein receptor gene

  1999cites this paper
• Opsporing van patiënten met familiaire hypercholesterolemie in Nederland

  1999cites this paper
• Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholesterolemia.

  1999cites this paper
• The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.

  1999cites this paper
• Genotype/phenotype correlations in familial hypercholesterolaemia.

  1998cites this paper
• Vascular Health and Risk Management Dovepress Optimal Management of Familial Hypercholesterolemia: Treatment and Management Strategies

  year unknowncites this paper